Roivant's Mosliciguat Posts Strong Phase 2 Result in PH-ILD — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Roivant is described as "one of the savviest dealmakers in biotech," a reputation reinforced by this week's clinical news
- Mosliciguat, Roivant's pipeline drug, achieved strong efficacy in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD)
- The PH-ILD Phase 2 results were reported this week and could open a new way to treat the serious lung disease, according to the article
- The clinical results could bolster Roivant's financial health with what the piece calls a "second blockbuster medicine"
- The drug's origins are described as "another fascinating aspect" of the story, surfaced in a subscriber-only analysis
Why it matters: PH-ILD patients currently have limited treatment options for a serious lung condition, so a successful mosliciguat would fill a real unmet need; for Roivant, a second blockbuster validates its strategy of acquiring and developing overlooked drug candidates and strengthens its financial position as a serial biotech dealmaker.
Ask SkimNews
